Localization defines streptozotocin/5-FU response in primary pancreatic neuroendocrine tumours

2021 ◽  
Author(s):  
Dominik Reher ◽  
Uli Fehrenbach ◽  
Antonin Kayser ◽  
Ulrich-Frank Pape ◽  
Frank Oliver Henes ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Pancreatic Neuroendocrine Tumours

Algorithm of diagnosis of pancreatic neuroendocrine tumours on fine needle aspiration specimens

2018 ◽  
Author(s):  
Cristiana Popp ◽  
Mirela Daiela Cioplea ◽  
Sabina Zurac ◽  
Patricia-Irina Stinga ◽  
Alexandra Ioana Dragusin ◽  
...  
Keyword(s):  
Fine Needle Aspiration ◽  
Neuroendocrine Tumours ◽  
Needle Aspiration ◽  
Fine Needle ◽  
Pancreatic Neuroendocrine Tumours

Imaging of Pancreatic-Neuroendocrine Tumours: An Outline of Conventional Radiological Techniques

2019 ◽  
Vol 12 (2) ◽  
pp. 135-155 ◽  
Author(s):  
Muhammad Affan Zamir ◽  
Wasim Hakim ◽  
Siraj Yusuf ◽  
Robert Thomas
Keyword(s):  
Neuroendocrine Tumours ◽  
Treatment Options ◽  
Advantages And Disadvantages ◽  
Imaging Characteristics ◽  
Fundamental Understanding ◽  
Pancreatic Neuroendocrine Tumours ◽  
Direct Management ◽  
Important Disease ◽  
Similar Imaging

IIntroduction: Pancreatic Neuroendocrine Tumours (p-NETs) are an important disease entity and comprise of peptide-secreting tumours often with a functional syndrome. : Accounting for a small percentage of all pancreatic tumours, they have a good overall survival rate when diagnosed early, with surgery being curative. The role of nuclear medicine in the diagnosis and treatment of these tumours is evident. However, the vast majority of patients will require extensive imaging in the form of conventional radiological techniques. It is important for clinicians to have a fundamental understanding of the p-NET appearances to aid prompt identification and to help direct management through neoplastic staging. Methods: This article will review the advantages and disadvantages of conventional radiological techniques in the context of p-NETs and highlight features that these tumours exhibit. Conclusion: Pancreatic neuroendocrine tumours are a unique collection of neoplasms that have markedly disparate clinical features but similar imaging characteristics. Most p-NETs are small and welldefined with homogenous enhancement following contrast administration, although larger and less welldifferentiated tumours can demonstrate areas of necrosis and cystic architecture with heterogeneous enhancement characteristics. : Prognosis is generally favourable for these tumours with various treatment options available. However, conventional radiological techniques will remain the foundation for the initial diagnosis and staging of these tumours, and a grasp of these modalities is extremely important for physicians.

Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours

2019 ◽  
Vol 12 (2) ◽  
pp. 126-134 ◽  
Author(s):  
Shahad Alsadik ◽  
Siraj Yusuf ◽  
Adil AL-Nahhas
Keyword(s):  
Side Effects ◽  
Effective Treatment ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Peptide Receptor Radionuclide Therapy ◽  
Progression Free Survival ◽  
Treatment Modalities ◽  
Effective Treatment Option ◽  
Peptide Receptor ◽  
Pancreatic Neuroendocrine Tumours

Background: The incidence of pancreatic Neuroendocrine Tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management. Objective: The aim of this review is to investigate the outcome of Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of pancreatic neuroendocrine tumours. Methods: A comprehensive literature search strategy was used based on two databases (SCOPUS, and PubMed). We considered all studies published in English, evaluating the use of PRRT (177Luteciuim- DOTA-conjugated peptides and 90Yetrium- DOTA- conjugated peptides) in the treatment of pancreatic neuroendocrine tumours as a standalone entity or as a subgroup within the wider category of Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs). Results: PRRT was found to be an effective treatment modality as a monotherapy or in combination with other therapies in the treatment of non-operable and metastatic pNETs where other options are limited. Complete response was reported to be between 2-6% while partial response was achieved in up to 60% of cases. Survival analysis was also impressive. Progression Free Survival (PFS) reached a mean of 34 months and Overall Survival (OS) of 53 months. PRRT also proved to improve patients’ Quality of Life (QoL). Acute and sub-acute side effects like nephrotoxicity and haematotoxicity are usually mild and reversible. Conclusion: PRRT is well tolerated and effective treatment option for non-operable and/or metastatic pNETs. Side effects are usually mild and reversible. Larger randomized controlled trails need to be done to compare PRRT with other treatment modalities and to provide more detailed guidelines regarding patient selections, the choice of PRRT, follow up and response assessment to maximum potential benefit.

Parathyroid Hormone-Related Peptide-Secreting Pancreatic Neuroendocrine Tumours: Case Series and Literature Review

2008 ◽  
Vol 89 (1) ◽  
pp. 48-55 ◽  
Author(s):  
Rajaventhan Srirajaskanthan ◽  
Mary McStay ◽  
Christos Toumpanakis ◽  
Tim Meyer ◽  
Martyn E. Caplin
Keyword(s):  
Parathyroid Hormone ◽  
Literature Review ◽  
Neuroendocrine Tumours ◽  
Case Series ◽  
Related Peptide ◽  
Pancreatic Neuroendocrine Tumours ◽  
Parathyroid Hormone Related Peptide

scholarly journals Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors

HPB ◽  
2007 ◽  
Vol 9 (5) ◽  
pp. 345-351 ◽  
Author(s):  
D. Gomez ◽  
H.Z. Malik ◽  
A. Al-Mukthar ◽  
K.V. Menon ◽  
G.J. Toogood ◽  
...  
Keyword(s):  
Hepatic Resection ◽  
Neuroendocrine Tumours ◽  
Prognostic Predictors ◽  
Pancreatic Neuroendocrine Tumours

Role of 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours

2011 ◽  
Vol 21 (11) ◽  
pp. 2408-2416 ◽  
Author(s):  
Rakesh Kumar ◽  
Punit Sharma ◽  
Pramod Garg ◽  
Sellam Karunanithi ◽  
Niraj Naswa ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Pet Ct ◽  
Pancreatic Neuroendocrine Tumours

Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumours

2021 ◽  
Author(s):  
Ophelie De Rycke ◽  
Thomas Walter ◽  
Marine Perrier ◽  
Olivia Hentic ◽  
Catherine Lombard-Bohas ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Objective Response ◽  
Multivariable Analysis ◽  
Progression Free Survival ◽  
Tumor Control ◽  
Free Survival ◽  
Mgmt Expression ◽  
Pancreatic Neuroendocrine Tumours

A rechallenge is common after initial efficacy of alkylating-based chemotherapy (ALK) in pancreatic neuroendocrine tumors (PanNET). High MGMT expression seems associated with lower response to ALK. We aimed to evaluate the efficacy and toxicity of ALK rechallenge in PanNET. Secondly, to assess the evolution of MGMT expression under ALK. All consecutive patients with advanced PanNETs who received initial ALK (achieving tumor control) followed by a pause > 3 months, then an ALK rechallenge (ALK2) upon progression were retrospectively studied (Cohort A). Primary endpoint was progression-free survival under ALK2 (PFS2). The MGMT expression was retrospectively assessed by immunohistochemistry (H-score) in consecutive PanNET surgically resected following ALK (Cohort B). We foud that cohort A included 62 patients (median Ki67 8%), for which ALK1 followed by pause achieved an objective response rate of 55%, and a PFS1 of 23.7 months (95% IC, 19.8-27.6). ALK2 achieved no objective response, and stability in 62% of patients. The median PFS2 was 9.2 months (IC 95% 7.1-11.3). At multivariable analysis, a hormonal syndrome (p=0.032) and a pause longer than 12 months (p=0.041) were associated with a longer PFS2. In the cohort B (17 patients), the median MGMT H-score increased from 45 (IQR 18-105) before ALK, to 100 (IQR 56-180) after ALK (p=0.003). We conclude that after initial efficacy of ALK treatment, a pause followed by ALK rechallenge might be appropriate to prolong tumor control, improve quality of life and limit long-term adverse events. Increased MGMT expression under ALK might explain low efficacy of ALK rechallenge.

scholarly journals Pancreatic neuroendocrine tumours in patients with von Hippel-Lindau disease

2020 ◽  
Vol 71 (3) ◽  
pp. 256-259
Author(s):  
Agnieszka Zwolak ◽  
Joanna Świrska ◽  
Ewa Tywanek ◽  
Marta Dudzińska ◽  
Jerzy S. Tarach ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Von Hippel Lindau ◽  
Von Hippel Lindau Disease ◽  
Pancreatic Neuroendocrine Tumours
Sign in / Sign up

Export Citation Format

Share Document